SUNNYVALE, California, May 12, 2026, 02:03 PDT
- Intuitive Surgical dropped 6.67% Monday, closing at $420.06—a 12-month low.
- Shares slid despite the da Vinci robot maker topping first-quarter revenue and profit forecasts back in April.
- Last week’s FDA Class I recall notice is now in the mix, with investors also factoring in softer 2026 procedure-growth forecasts and fresh competitive heat coming from Medtronic and Johnson & Johnson.
Shares of Intuitive Surgical dropped to a new 52-week low on Monday, deepening this year’s steep 2026 selloff. Demand for its da Vinci surgical robots has remained strong, but that hasn’t stopped the slide.
Intuitive shares dropped 6.67% to finish at $420.06 on Nasdaq, down from Friday’s $450.06 close. The stock touched an intraday low of $417.74 before settling. That slide sent Intuitive back to pricing not seen since before the most recent da Vinci 5-driven rally.
The drop takes on new weight: Intuitive isn’t just a growth story anymore. Investors are probing whether a high-valuation medtech name can hold up as regulators, tariffs, and rivals all press in.
Growth hasn’t slowed for Intuitive. First-quarter revenue jumped 23% to $2.77 billion, with adjusted earnings at $2.50 per share—topping Wall Street forecasts, according to Reuters. The company placed 431 da Vinci systems in the quarter, of which 232 were the new da Vinci 5 model, it said.
Chief Executive Dave Rosa credited the quarter’s results to broader uptake of the company’s da Vinci, Ion, and digital systems, according to the April earnings release. Ion is Intuitive’s robotic platform designed for lung biopsy, a procedure that collects tissue from the lung.
The numbers haven’t quieted the debate. Intuitive’s forecast for da Vinci-assisted procedures calls for a 13.5% to 15.5% global increase in 2026—lower than the 18% reported for 2025, but a notch above what the company had previously projected. Procedure growth remains in focus, as each surgery typically boosts instrument and accessory sales.
Mike Kratky at Leerink Partners sounded an optimistic note after April’s numbers, telling Investor’s Business Daily that “strong 1Q results keep us positive on ISRG’s outlook.” Yet, despite those fundamentals, a handful of firms trimmed their price targets following the report—pressure from stretched medtech valuations is still weighing on the stock. Investors
Pricing in the regulatory risk is no simple task. On May 5, the U.S. Food and Drug Administration slapped a Class I tag—the agency’s highest risk level—on Intuitive’s recall of some 8mm SureForm 30 gray reloads. According to the FDA, using the affected devices could result in serious injury or even death. Intuitive reported four serious injuries and a single fatality linked to incomplete staple lines, with incidents tallied as of Feb. 23.
These reloads work with certain da Vinci systems to cut and seal tissue and blood vessels. The FDA noted that Intuitive asked customers to pull the products from use, set them aside, and switch to other options.
Competition is no longer just hypothetical. Medtronic’s Hugo robotic-assisted surgery system picked up U.S. FDA clearance for urologic procedures in December, marking a shift that Medtronic executive Rajit Kamal summed up as: “there is now choice” for hospitals adding robotic programs. Reuters described Hugo as the first meaningful rival to Intuitive in the robotic-assisted surgery space. Medtronic News
Last week, Johnson & Johnson ramped up the pressure, reporting that its investigational OTTAVA robotic surgical system hit primary safety and performance goals in a 30-patient gastric-bypass trial. Every procedure ran entirely on the robot—no switches to traditional surgery needed. While OTTAVA isn’t an immediate commercial rival, the move gives investors something new to track outside of Intuitive.
There’s a balancing factor here. Intuitive’s board bumped its share buyback authorization up to $5.0 billion as of April 30—this figure folds in leftover amounts from previous green lights, per a recent filing. The company noted that repurchases might pause or stop altogether, depending on how the market shapes up.
The danger here: the selloff might stick around longer than bulls hope. Intuitive flagged tariffs, inflation, supply chain snags, delayed hospital budgets, and global credit as headwinds that could bite into performance. Should procedure growth fall off more sharply than management projects—or if recall investigations expand—investors could keep marking down the multiple on this surgical robotics leader.
